A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments

QR Code

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments

Laura M Periman,1 Francis S Mah,2 Paul M Karpecki3 1Periman Eye Institute, Seattle, WA, USA; 2Scripps Health, La Jolla, CA, USA; 3Kentucky Eye Institute, Lexington, KY, USACorrespondence: Laura M PerimanPeriman Eye Institute, Seattle, WA, USAEmail dryeyemaster@gmail.comAbstract: Dry eye disease (DED...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Periman LM, Mah FS, Karpecki PM
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2020
Sujets:	dry eye disease cyclosporine a emulsion otx-101 keratoconjunctivitis sicca Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/fae4aabda76641bc982bd5717d067a8c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
par: Jerkins GW, et autres
Publié: (2020)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
par: de Oliveira RC, et autres
Publié: (2019)

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
par: Sheppard J, et autres
Publié: (2021)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
par: Pisella P, et autres
Publié: (2018)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
par: Burade V, et autres
Publié: (2020)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
par: White DE, et autres
Publié: (2019)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
par: Rhee MK, et autres
Publié: (2017)

Acupuncture and dry eye: current perspectives. A double-blinded randomized controlled trial and review of the literature
par: Dhaliwal DK, et autres
Publié: (2019)

Dry Eye Syndrome and Sicca Complex are Commonly Found in Patients with Postural Orthostatic Tachycardia Syndrome
par: Ho DS, et autres
Publié: (2020)

Cyclosporine A micellar delivery system for dry eyes
par: Kang H, et autres
Publié: (2016)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
par: Deveney T, et autres
Publié: (2018)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
par: Matossian C, et autres
Publié: (2021)

Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis
par: Groß D, et autres
Publié: (2017)

Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
par: Shen Lee B, et autres
Publié: (2020)

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
par: Karpecki PM, et autres
Publié: (2019)

Effect of Cyclosporine 0.09% Treatment on Accuracy of Preoperative Biometry and Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery
par: Hovanesian JA, et autres
Publié: (2021)

Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
par: Nebbioso M, et autres
Publié: (2019)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
par: Stonecipher KG, et autres
Publié: (2016)

Effectiveness of Subconjunctival Cyclosporine in Treatment of Acute Allergic Conjunctivitis in a Rat-Model
par: Awara A, et autres
Publié: (2020)

Improving Tolerance and Compliance with Topical Immunomodulators Using Micro-Emulsion Lipid Layer Artificial Tears
par: Epitropoulos AT, et autres
Publié: (2020)

A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease
par: Friedman NJ, et autres
Publié: (2016)

Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
par: Rush SW, et autres
Publié: (2021)

Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye
par: Sambursky R
Publié: (2016)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
par: Tauber J, et autres
Publié: (2018)

Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease
par: White DE, et autres
Publié: (2020)

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
par: White DE, et autres
Publié: (2020)

Effect of Erythromycin on the Intestinal Transport of Cyclosporine
par: P Zakeri Milani,, et autres
Publié: (2009)

Remission of Kimura Disease With Carotid Hypervascularization After Cyclosporine Treatment
par: Severino Persechino, et autres
Publié: (2020)

A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease
par: Jerkins G, et autres
Publié: (2020)

Making the diagnosis of Sjögren’s syndrome in patients with dry eye
par: Beckman KA, et autres
Publié: (2015)

Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
par: Torkildsen G, et autres
Publié: (2017)

Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies
par: Li Y, et autres
Publié: (2020)

Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial
par: Silverstein S, et autres
Publié: (2020)

Efficacy and Safety of Phospholipid Nanoemulsion-Based Ocular Lubricant for the Management of Various Subtypes of Dry Eye Disease: A Phase IV, Multicenter Trial
par: Yeu E, et autres
Publié: (2020)

Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
par: Yeu E, et autres
Publié: (2019)

Topical Cyclosporine in Oral Lichen Planus—A Series of 21 Open-Label, Biphasic, Single-Patient Observations
par: Babak Monshi, et autres
Publié: (2021)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
par: McMullin D, et autres
Publié: (2021)

Treatment of chronic dry eye: focus on cyclosporine
par: George D Kymionis, et autres
Publié: (2008)

Cyclosporine Biosynthesis in <italic toggle="yes">Tolypocladium inflatum</italic> Benefits Fungal Adaptation to the Environment
par: Xiuqing Yang, et autres
Publié: (2018)

Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
par: Jariyakosol S, et autres
Publié: (2021)